News
![BitNile Holdings’ Subsidiary, Digital Power Lending, Makes Strategic Investment in Lab-Grown Diamond Manufacturer: https://mms.businesswire.com/media/20220512005443/en/1267458/5/Bitnile_Logo_%28300ppi%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFYzV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a7aeaf571405e3bfd1320d7e8c956bc4d6f11368/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Bitnile_Logo_-28300ppi-29.jpg?locale=us)
BitNile Holdings’ Subsidiary, Digital Power Lending, Makes Strategic Investment in Lab-Grown Diamond Manufacturer
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) announced today that its subsidiary, Digital Power Lending, LLC (“DP Lending”), has lent
![PAO Severstal: Notice on payment](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
PAO Severstal: Notice on payment
![Uni-Bio Science Group Limited: 2022 Interim Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Uni-Bio Science Group Limited: 2022 Interim Results
![DGAP-Adhoc: Uniper fully uses existing KfW credit facility and applies for extension of KfW credit facility](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-Adhoc: Uniper fully uses existing KfW credit facility and applies for extension of KfW credit facility
![Aroundtown SA: Release of a capital market information](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Aroundtown SA: Release of a capital market information
![DGAP-News: Deutsche Postbank Funding Trust III announces the Netherlands as its home member state](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Deutsche Postbank Funding Trust III announces the Netherlands as its home member state
![DGAP-Adhoc: Greiffenberger AG: Changes in the Management Board](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-Adhoc: Greiffenberger AG: Changes in the Management Board
![Deufol SE: Results for the first half of 2022](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Deufol SE: Results for the first half of 2022
![Sistema PJSFC: Sistema announces financial results for the second quarter 2022](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Sistema PJSFC: Sistema announces financial results for the second quarter 2022
![Affluent Medical : Affluent Medical announces the launch of a capital increase with preferential subscription rights (PSR)](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Affluent Medical : Affluent Medical announces the launch of a capital increase with preferential subscription rights (PSR)
![DGAP-News: European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2
![Cairn Homes Plc: Transaction in Own Shares](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Cairn Homes Plc: Transaction in Own Shares
![DGAP-News: BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-News: BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting
![Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
![Markus Heusser proposed for election as Chairman of the Board of Directors and successor to Urs Kaufmann](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Markus Heusser proposed for election as Chairman of the Board of Directors and successor to Urs Kaufmann
![Ranger Energy Services, Inc. to Present at the Barclays CEO Energy-Power Conference: https://mms.businesswire.com/media/20210127005996/en/855199/5/RangerLogo-HighResolution-2560x1509.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUgxVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fa1fc04022d526e99fddb75bd39fd77ef7e084d9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/RangerLogo-HighResolution-2560x1509.jpg?locale=us)
Ranger Energy Services, Inc. to Present at the Barclays CEO Energy-Power Conference
Ranger Energy Services, Inc. (NYSE:RNGR) (the “Company”) today announced that Stuart Bodden, Chief Executive Officer, and Melissa Cougle, Chief Financial Officer, will present to members of the
![NuStar Energy L.P.’s 2021 Schedule K-3 Now Available: https://pixabay.com/de/photos/gegens%C3%A4tze-daumen-positiv-negativ-3808487/](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3k2TkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f776707cce89379fb9ac511edf9a702744c9554e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/opposites-3808487_1280.jpg?locale=us)
NuStar Energy L.P.’s 2021 Schedule K-3 Now Available
NuStar Energy, L.P. (NYSE: NS) today announced that its 2021 Schedule K-3, reflecting items of international tax relevance, is available online. Unitholders requiring this information may access
![Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted
![Rights and Issues Investment Trust PLC: Transaction in Own Shares](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Rights and Issues Investment Trust PLC: Transaction in Own Shares
![Savara Announces Resignation of Chief Medical Officer: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXNWUlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--30282242e6a53f7234dfd6a72990cb1138b07d13/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SavaraLogo.jpg?locale=us)
Savara Announces Resignation of Chief Medical Officer
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief
![DGAP-Adhoc: Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
DGAP-Adhoc: Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
![Power Integrations to Participate in Deutsche Bank Technology Conference: https://mms.businesswire.com/media/20191127005086/en/440630/5/PI_Logo_Short_black_blue_RGB150.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5pRXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb2327bc893fbe83c7816809a159f0259f3298c3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/PI_Logo_Short_black_blue_RGB150.jpg?locale=us)
Power Integrations to Participate in Deutsche Bank Technology Conference
Power Integrations (Nasdaq: POWI) today announced that Sandeep Nayyar, the company’s chief financial officer, will participate in a fireside chat at the Deutsche Bank Technology Conference on
![Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc
![Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
![Form 8.3 - The Vanguard Group, Inc.: Meggitt plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)